Medindia LOGIN REGISTER
Medindia
Advertisement

Health Canada Approves Taltz® (ixekizumab) for Treatment of Active Psoriatic Arthritis

Wednesday, June 20, 2018 General News
Advertisement

____________________________

i Taltz® Canadian Product Monograph, March 29, 2018.

ii Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957-970.

iii Arthritis Society. What is psoriatic arthritis?. Available at: https://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis. Accessed May 7, 2018.

iv Papp K, Valenzuela F, Poulin Y, Bernstein G, Wasel N. Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. J Cutan Med Surg. 2010;14(4):167-74.

v Arthritis Society. What is psoriatic arthritis?. Available at: https://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis. Accessed April 18, 2018.

vi Arthritis Society. Symptoms of PsA. Available at: https://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis. Accessed April 18, 2018.

vii Taltz® Canadian Product Monograph, March 29, 2018.

viii Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957-970.

ix Gladman DD. Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):569-79.

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close